{"id":3953,"date":"2022-04-29T15:45:53","date_gmt":"2022-04-29T19:45:53","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/"},"modified":"2026-09-24T00:07:06","modified_gmt":"2026-09-24T04:07:06","slug":"gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/","title":{"rendered":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021"},"content":{"rendered":"\n<strong>\u00a0<\/strong><strong>Paris, France, Friday April 29, 2022, 5:45 pm CEST<\/strong> \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market authority (<em>Autorit\u00e9s des March\u00e9s Financiers<\/em>, or AMF) under the reference D.22-0390.\n\n&nbsp;\n\nThe universal registration document notably includes:\n<ul>\n \t<li>the 2021 annual financial report;<\/li>\n \t<li>the management report;<\/li>\n \t<li>the report on corporate governance; and<\/li>\n \t<li>the description of the share buyback program.<\/li>\n<\/ul>\n&nbsp;\n\nThis universal registration document may be consulted on the Company\u2019s website (<span style=\"color: #33bdbc\"><a style=\"color: #33bdbc\" href=\"https:\/\/www.gensight-biologics.com\">www.gensight-biologics.com<\/a><\/span>), \u201cInvestors\u201d section, and on the AMF\u2019s website (<span style=\"color: #33bdbc\">www.amf-france.org<\/span>).\n\n&nbsp;\n\n&nbsp;\n\n<span style=\"color: #33bdbc\"><strong>About GenSight Biologics <\/strong><\/span>\n\nGenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics\u2019 pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics\u2019 lead product candidate, LUMEVOQ<sup>\u00ae<\/sup> (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics\u2019 product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Paris, France, Friday April 29, 2022, 5:45 pm CEST \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[76,80],"post-year":[],"class_list":["post-3953","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-type-corporate","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"\u00a0Paris, France, Friday April 29, 2022, 5:45 pm CEST \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-29T19:45:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:06+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021\",\"datePublished\":\"2022-04-29T19:45:53+00:00\",\"dateModified\":\"2026-09-24T04:07:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/\"},\"wordCount\":259,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/\",\"name\":\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-04-29T19:45:53+00:00\",\"dateModified\":\"2026-09-24T04:07:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/04\\\/29\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021 - GenSight Biologics","og_description":"\u00a0Paris, France, Friday April 29, 2022, 5:45 pm CEST \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/","og_site_name":"GenSight Biologics","article_published_time":"2022-04-29T19:45:53+00:00","article_modified_time":"2026-09-24T04:07:06+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021","datePublished":"2022-04-29T19:45:53+00:00","dateModified":"2026-09-24T04:07:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/"},"wordCount":259,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/","name":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2022-04-29T19:45:53+00:00","dateModified":"2026-09-24T04:07:06+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/04\/29\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3953"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3953\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3953"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3953"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3953"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3953"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}